Startseite Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy

  • Gabriella Bekő , Henriett Butz , Klára Berta , András Tislér , Ferenc Olajos , Barna Vásárhelyi und Attila Patócs EMAIL logo
Veröffentlicht/Copyright: 8. Dezember 2012
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Clinical guidelines for decision-making in chronic kidney disease (CKD) consider parathormone (PTH) levels. The measured PTH values differ if novel full length PTH(1-84) assays are used instead of earlier intact iPTH assays. In this study we analyzed how the classification of CKD patients alters when iPTH assays are switched to PTH(1-84) assays.

Methods: Plasma samples were collected prior to dialysis sessions from 110 consecutive CKD patients on maintenance hemodialysis. PTH levels were determined with iPTH assays (Elecsys, Architect and DiaSorin Liaison N-tact) and PTH(1-84) assays (Elecsys and Liaison). Using KDIGO guidelines patients were classified as being below, above and in the recommended target range (RTR) of PTH. The results of classification with different assays were evaluated and, a novel calculation method of RTR was implemented.

Results: The prevalence of patients with PTH in RTR is comparable with each assay, but the individual patients differed. PTH(1-84) Elecsys and Liaison assays classified more patients as being below RTR than iPTH Elecsys and Architect but not Liaison N-tact assay (27.3%, 22.7% vs. 41%, 31.8%, and 36.4%, respectively). In turn, PTH(1-84) Elecsys and Liaison assays identified less CKD patients with PTH above the RTR than iPTH except N-tact assays (6.4%, 10% vs. 16.3%, 19%, and 6.3%, respectively). Using our calculation method, our discrimination values for PTH(1-84) assays to achieve classification identical to that with iPTH Elecsys were lower than those recommended by the manufacturer.

Conclusions: Current guidelines for the treatment of secondary hyperparathyroidism in CKD should consider the type of assays used for PTH measurement. Each laboratory should assess its own RTR for PTH tests to achieve comparable classification. The presented calculation is simple, it mimics an everyday situation, switching from one assay to another one, and provides useful RTR values for PTH tests.


Corresponding author: Dr. Attila Patócs, MD, MSc, PhD, Department of Laboratory Medicine Institute, Central Isotope Laboratory, Semmelweis University 1088 Budapest, Szentkirályi u. 46, Hungary, Phone: +36 1 2660926 ext 55577, Fax: +36 1 2664616

This work was granted by TÁMOP 4.2.2.B-10/1. Attila Patocs is a recipient of the Janos Bolyai fellowship.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Friedman PA, Goodman WG. PTH(1-84)/PTH(7–84): a balance of power. Am J Physiol Renal Physiol 2006;290:F975–84.10.1152/ajprenal.00336.2005Suche in Google Scholar

2. Stokes FJ, Ivanov P, Bailey LM, Fraser WD. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011;57:138–40.10.1373/clinchem.2010.157289http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000285686100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

3. Sturgeon CM, Seth J. Why do immunoassays for tumour markers give differing results? A view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Clin Biochem 1996;34:755–9.Suche in Google Scholar PubMed

4. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987–95.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000256551700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1053/j.ajkd.2008.01.017Suche in Google Scholar PubMed

5. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240–3.10.1038/sj.ki.5001658Suche in Google Scholar PubMed

6. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 117. Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis Therapy, 2007. Available from: http://guidance.nice.org.uk/nicemedia/live/11608/33857/33857.pdf. Accessed 10 January, 2011.Suche in Google Scholar

7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;113:S1–130.Suche in Google Scholar

8. Steddon S, Sharples E. Renal Association Clinical Practice Guideline: CKD-Mineral and Bone Disorders (CKD-MBD), 2011. Available from: http://www.renal.org/clinical/GuidelinesSection/CKD-MBD.aspx. Accessed 10 September.10.1159/000328066Suche in Google Scholar

9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.10.7326/0003-4819-139-2-200307150-00013Suche in Google Scholar PubMed

10. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease 2003. Am J Kidney Dis 2003;42:S1–201.10.1016/S0272-6386(03)00905-3Suche in Google Scholar

11. Waller S, Ridout D, Cantor T, Rees L. Differences between “intact” PTH and 1-84 PTH assays in chronic renal failure and dialysis. Pediatr Nephrol 2005;20:197–9.10.1007/s00467-004-1735-2Suche in Google Scholar PubMed

12. Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605–14.10.1359/jbmr.2001.16.4.605Suche in Google Scholar PubMed

13. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287–90.10.1210/jcem.84.11.6236Suche in Google Scholar PubMed

14. La’ulu SL, Roberts WL. Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 2010;134: 930–8.10.1309/AJCPLGCZR7IPVHA7Suche in Google Scholar PubMed

15. Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011;15(Suppl 1): 42–9.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000292544600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1111/j.1744-9987.2011.00926.xSuche in Google Scholar PubMed

16. Almond A, Ellis AR, Walker SW. On behalf of the scottish clinical biochemistry managed diagnostic network. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299984500010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1258/acb.2011.011094Suche in Google Scholar PubMed

17. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results – a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440–5.10.1093/ndt/gfr614Suche in Google Scholar PubMed PubMed Central

18. Souberbielle J-C, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010;48:769–74.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279342700006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1515/CCLM.2010.157Suche in Google Scholar PubMed

19. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52: 1771–6.10.1373/clinchem.2006.071589Suche in Google Scholar PubMed

20. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012;27:1950–6.10.1093/ndt/gfr535Suche in Google Scholar PubMed

Received: 2012-07-23
Accepted: 2012-11-07
Published Online: 2012-12-08
Published in Print: 2013-06-01

©2013 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Letters to the Editor
  2. Evaluation of a novel room temperature RNA storage tube for use in a real-time quantitative PCR assay
  3. Evaluation of the Universal Master Mix (STAT-NAT DNA-Mix) for reliable molecular testing
  4. HbA1c: performance of the Sebia Capillarys 2 Flex Piercing
  5. A case of monoclonal gammopathy of undetermined significance (MGUS): type IgD-lambda
  6. Evidence-based use of serum protein electrophoresis in laboratory medicine
  7. Plasma volume shifts during multiday racing
  8. Structured handoff at shift change in a clinical laboratory increases patient safety
  9. Instrument-dependent interference of Howell-Jolly bodies in reticulocyte enumeration
  10. Reply to Gore et al.: Plasma volume shift during multiday racing
  11. Recommendations for appropriate serum electrophoresis requests: the Italian approach
  12. Masthead
  13. Masthead
  14. Editorials
  15. Biomarkers for sepsis: an unfinished journey
  16. Laboratory demand management of repetitive testing – time for harmonisation and an evidenced based approach
  17. Reviews
  18. Non-invasive prenatal diagnostics of aneuploidy using next-generation DNA sequencing technologies, and clinical considerations
  19. The diagnostic utility of brain natriuretic peptide in heart failure patients presenting with acute dyspnea: a meta-analysis
  20. Opinion Paper
  21. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department
  22. Genetics and Molecular Diagnostics
  23. Microarray with LNA-probes for genotyping of polymorphic variants of Gilbert’s syndrome gene UGT1A1(TA)n
  24. Selection of the optimal manual method of cell free fetal DNA isolation from maternal plasma
  25. A multiplex assay to rapidly exclude HLA-DQ2.5 and HLA-DQ8 expression in patients at risk for celiac disease
  26. Low cost biosensor-based molecular differential diagnosis of α-thalassemia (Southeast Asia deletion)
  27. General Clinical Chemistry and Laboratory Medicine
  28. Managing laboratory test ordering through test frequency filtering
  29. Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation
  30. Long-term stability of laboratory tests and practical implications for quality management
  31. Coffee consumption, serum γ-glutamyltransferase, and glucose tolerance status in middle-aged Japanese men
  32. Biological variation and prognosis usefulness of new biomarkers in liver transplantation
  33. Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy
  34. A comparison between two different in vitro basophil activation tests for gluten- and cow’s milk protein sensitivity in irritable bowel syndrome (IBS)-like patients
  35. A proficiency testing program of hemoglobin analysis in prevention and control of severe hemoglobinopathies in Thailand
  36. Advancing haemostasis automation – successful implementation of robotic centrifugation and sample processing in a tertiary service hospital
  37. ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome
  38. Analysis of serous body fluids using the CELL-DYN Sapphire hematology analyzer
  39. Cancer Diagnostics
  40. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer
  41. Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE)
  42. Cardiovascular Diseases
  43. Additional diagnostic and prognostic value of copeptin ultra-sensitive for diagnosis of non-ST-elevation myocardial infarction in older patients presenting to the emergency department1)
  44. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality
Heruntergeladen am 14.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0485/html
Button zum nach oben scrollen